GLP-1 Market
LLY $1208.74 ▲ +3.6% NVO $38.12 ▲ +0.2% PFE $29.21 ▲ +3.0% VKTX $25.47 ▼ -4.4% KLRA $10.74 ▼ -0.3% GPCR $21.88 ▼ -1.9% RHHBY $55.67 ▲ +3.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

0.75% Phentolamine Ophthalmic

Company
Opus Genetics, Inc
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 15, 2026

Find a Clinical Trial Near Me

See recruiting studies for 0.75% Phentolamine Ophthalmic and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07140783

    OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

    Not yet reported Opus Genetics, Inc 580 participants Est. completion 2027-08 20 sites Stand-alone
    Other conditions: Vision Loss Night, Vision Disorders
    View official trial listing →
  • Completed NCT NCT04620213

    Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

    Not yet reported Opus Genetics, Inc 185 participants Est. completion 2021-03-15 12 sites Stand-alone
    Other conditions: Mydriasis, Dilation
    View official trial listing →
  • Completed NCT NCT04638660

    Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

    Not yet reported Opus Genetics, Inc 144 participants Est. completion 2022-05-19 17 sites Stand-alone
    Other conditions: Dim Light Vision Disturbances
    View official trial listing →
  • Completed NCT NCT04675151

    Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

    Not yet reported Opus Genetics, Inc 150 participants Est. completion 2021-06-30 17 sites Stand-alone
    Other conditions: Presbyopia
    View official trial listing →
  • Completed NCT NCT05134974

    Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

    Not yet reported Opus Genetics, Inc 368 participants Est. completion 2022-03-29 15 sites
    Other conditions: Mydriasis, Dilation
    View official trial listing →
  • Completed NCT NCT05223478

    Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

    Not yet reported Opus Genetics, Inc 23 participants Est. completion 2022-04-28 2 sites
    Other conditions: Mydriasis, Dilation
    View official trial listing →
  • Completed NCT NCT06349759

    Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

    Not yet reported Opus Genetics, Inc 200 participants Est. completion 2026-02-19 25 sites
    Other conditions: Mesopic Vision, Night Vision Loss
    View official trial listing →
  • Completed NCT NCT06542497

    Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

    Not yet reported Opus Genetics, Inc 569 participants Est. completion 2026-01-22 39 sites
    Other conditions: Presbyopia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: 0.75% Phentolamine Ophthalmic, 0.75% Phentolamine Ophthalmic Solution

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.